Early mortality in elderly patients undergoing treatment for multiple myeloma in real-world practice

被引:10
|
作者
Xia, Jun [1 ]
Wang, Lingling [1 ]
Zhou, Xin [1 ]
Wang, Jing [1 ]
Wang, Huan [1 ]
Guo, Hongfeng [1 ]
机构
[1] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Hematol, 299 Qingyang Rd, Wuxi 214023, Peoples R China
关键词
Elderly; multiple myeloma; early mortality; bortezomib; International Staging System; lactate dehydrogenase; CLINICAL-FEATURES; STAGING SYSTEM; THERAPY; AGE; MANAGEMENT; SURVIVAL;
D O I
10.1177/0300060518757640
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives This study was performed to analyze the risk factors for early mortality (EM) in elderly patients undergoing treatment for multiple myeloma (MM) in real-world clinical practice. Methods Retrospective data from 108 elderly patients who were newly diagnosed with MM from January 2007 to July 2015 were analyzed in a single hematology center. EM was defined as death of any cause within 12 months after diagnosis. A multivariate regression model was used to evaluate EM. Results EM occurred in 16 (14.8%) elderly patients with newly diagnosed MM. The most common cause of death was infection (10/16, 62.5%). In the multivariate analysis, only an age of 75 years, International Staging System (ISS) stage III disease, and high lactate dehydrogenase concentration were significantly and independently associated with EM. Conclusion Our results suggest that infection is the leading cause of EM in elderly patients with MM. An age of 75 years, ISS stage III disease, and a high lactate dehydrogenase concentration are significant predictors of EM. We should further target this higher-risk patient population to define personalized therapy with which to improve outcomes.
引用
收藏
页码:2230 / 2237
页数:8
相关论文
共 50 条
  • [21] Treatment landscape and disease burden of patients with multiple myeloma in Japan: a real-world survey
    Yasutomi, Yusuke
    Ribbands, Amanda
    Luke, Emily
    Mcnamara, Simon
    FUTURE ONCOLOGY, 2025, 21 (06) : 681 - 690
  • [22] Current Real-World Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeannene
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne
    BLOOD, 2018, 132
  • [23] Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada
    Jimenez-Zepeda, Victor H.
    Chen, Guanmin
    Shaw, Eileen
    Farris, Megan S.
    Cowling, Tara
    Tay, Jason
    LEUKEMIA & LYMPHOMA, 2022, 63 (11) : 2557 - 2564
  • [24] SURVIVAL AND TREATMENT PATTERNS IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA (MM) IN A REAL-WORLD SETTING
    Hajek, R.
    Jarkovsky, J.
    Maisnar, V.
    Pour, L.
    Spicka, I.
    Minarik, J.
    Gregora, E.
    Kessler, P.
    Sykora, M.
    Frankova, H.
    Adamova, D.
    Wrobel, M.
    Mikula, P.
    Campioni, M.
    DeCosta, L.
    Treur, M.
    Gonzalez-McQuire, S.
    Bouwmeester, W.
    HAEMATOLOGICA, 2016, 101 : 529 - 529
  • [25] The real-world outcomes of multiple myeloma patients treated with daratumumab
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Gjerdrum, Lise Mette Rahbek
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Dokhi, Marveh
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    PLOS ONE, 2021, 16 (10):
  • [26] Symptom experience of patients undergoing treatment for multiple myeloma: a longitudinal real-world electronic patient-reported outcomes study
    Patel, Mihir N.
    Nina, Anneli
    Branchaud, Brenda
    Herring, Kris W.
    Johnson, Suzanne
    Scott, Julie
    LeBlanc, Thomas W.
    SUPPORTIVE CARE IN CANCER, 2024, 32 (12)
  • [27] Real-World Clinical Outcomes in Elderly Chinese Patients with Multiple Myeloma: A Single-Center Experience
    Qian, Xifeng
    Chen, Heng
    Xia, Jun
    Wang, Jing
    Zhou, Xin
    Guo, Hongfeng
    MEDICAL SCIENCE MONITOR, 2018, 24 : 5887 - 5893
  • [28] Recent Advances in Multiple Myeloma: Applying Real-world Evidence to Clinical Practice
    Fonseca, Rafael
    Costa, Luciano
    Nooka, Ajay K.
    Pianko, Matthew James
    ONCOLOGY-NEW YORK, 2022, 36 (08): : 506 - 510
  • [29] Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice
    Hulin, Cyrille
    de la Rubia, Javier
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Katodritou, Eirini
    Hungria, Vania
    De Samblanx, Hadewijch
    Stoppa, Anne-Marie
    Aagesen, Jesper
    Sargin, Deniz
    Sioni, Anastasia
    Belch, Andrew
    Diels, Joris
    Olie, Robert A.
    Robinson, Don, Jr.
    Potamianou, Anna
    van de Velde, Helgi
    Delforge, Michel
    HEALTH SCIENCE REPORTS, 2019, 2 (01)
  • [30] Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma
    Sokol, Juraj
    Guman, Tomas
    Chudej, Juraj
    Hlebaskova, Monika
    Stecova, Natalia
    Valekova, Lubica
    Kucerikova, Monika
    Stasko, Jan
    ANNALS OF HEMATOLOGY, 2022, 101 (01) : 81 - 89